[Pathogenetic substantiation of using peptidases in the treatment of patients with generalized periodontitis].

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

76 patients of whom 52 patients with GP-II degree exacerbative and 24 somatically healthy people aged 20-50 years were studied. Based on these immunological examination serapeptydase was assigned per os, as a complementary product to the basic therapy. Any concentration of secretory leukocyte protease inhibitor (SLPI) indicates the dominant hyperergic inflammation in periodontal tissues, accompanied by increased proteolysis. Profitable accumulation in the serum of patients with GP inhibitors proteinase to 53%, IL-1beta - to 26.3%, IL-2 - to 19.5%, IL-8 - to 42.8% FNPalpha - up to 48.3%, and reduction of IFNalpha to 78.1% indicates changes of complex "protease-antiproteases" immunocompetent cells and activation of inflammatory processes at the local and systemic levels.

Cite

CITATION STYLE

APA

Serheieva, I. I. (2013). [Pathogenetic substantiation of using peptidases in the treatment of patients with generalized periodontitis]. Fiziolohichnyǐ Zhurnal (Kiev, Ukraine : 1994), 59(2), 85–91. https://doi.org/10.15407/fz59.02.085

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free